Envestnet Portfolio Solutions Inc. Boosts Stock Position in Kenvue Inc. $KVUE

Envestnet Portfolio Solutions Inc. boosted its holdings in Kenvue Inc. (NYSE:KVUE) by 0.6% during the 2nd quarter, Holdings Channel reports. The firm owned 301,231 shares of the company’s stock after acquiring an additional 1,895 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Kenvue were worth $6,305,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of KVUE. Vanguard Group Inc. boosted its position in Kenvue by 4.9% in the first quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company’s stock worth $5,494,882,000 after purchasing an additional 10,600,682 shares during the last quarter. Third Point LLC bought a new stake in shares of Kenvue in the first quarter valued at $213,422,000. Maverick Capital Ltd. bought a new stake in shares of Kenvue in the first quarter valued at $203,036,000. Nuveen LLC bought a new stake in shares of Kenvue in the first quarter valued at $187,123,000. Finally, Voya Investment Management LLC raised its stake in shares of Kenvue by 131.3% in the first quarter. Voya Investment Management LLC now owns 12,131,468 shares of the company’s stock valued at $290,557,000 after buying an additional 6,886,784 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

KVUE has been the topic of several research reports. Canaccord Genuity Group lowered their target price on Kenvue from $29.00 to $26.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Citigroup lowered their target price on Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, October 9th. Redburn Partners set a $22.00 target price on Kenvue in a research note on Friday, September 26th. UBS Group decreased their price objective on Kenvue from $23.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 8th. Finally, Bank of America decreased their price objective on Kenvue from $25.00 to $21.00 and set a “buy” rating on the stock in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Kenvue has a consensus rating of “Hold” and a consensus target price of $21.18.

Kenvue Stock Performance

NYSE:KVUE opened at $16.18 on Wednesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. Kenvue Inc. has a 52-week low of $15.47 and a 52-week high of $25.17. The firm has a market cap of $31.04 billion, a price-to-earnings ratio of 21.86, a PEG ratio of 2.33 and a beta of 0.72. The business’s fifty day moving average is $18.92 and its 200 day moving average is $21.22.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. The business had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The company’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Research analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were paid a $0.2075 dividend. The ex-dividend date was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a yield of 5.1%. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio is currently 112.16%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.